These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28574407)

  • 21. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated satellite cell number in Duchenne muscular dystrophy.
    Kottlors M; Kirschner J
    Cell Tissue Res; 2010 Jun; 340(3):541-8. PubMed ID: 20467789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C.
    Villa CR; Kaddourah A; Mathew J; Ryan TD; Wong BL; Goldstein SL; Jefferies JL
    Neuromuscul Disord; 2016 Oct; 26(10):637-642. PubMed ID: 27542440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.
    Lit L; Sharp FR; Apperson M; Liu DZ; Walker WL; Liao I; Xu H; Ander BP; Wong B
    Pharmacogenomics J; 2009 Dec; 9(6):411-8. PubMed ID: 19488064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
    Dooley JM; Bobbitt SA; Cummings EA
    Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy.
    Parreira SL; Resende MB; Della Corte Peduto M; Marie SK; Carvalho MS; Reed UC
    Arq Neuropsiquiatr; 2007 Jun; 65(2A):245-50. PubMed ID: 17607422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
    Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
    Biggar WD; Harris VA; Eliasoph L; Alman B
    Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril.
    Mavrogeni S; Giannakopoulou A; Papavasiliou A; Markousis-Mavrogenis G; Pons R; Karanasios E; Noutsias M; Kolovou G; Papadopoulos G
    BMC Cardiovasc Disord; 2017 Jul; 17(1):197. PubMed ID: 28738778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents.
    Herbelet S; Rodenbach A; Paepe B; De Bleecker JL
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
    Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
    Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
    [No Abstract]   [Full Text] [Related]  

  • 33. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
    Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
    Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.
    Angelini C; Peterle E
    Acta Myol; 2012 May; 31(1):9-15. PubMed ID: 22655511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
    McAdam LC; Mayo AL; Alman BA; Biggar WD
    Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Glemser PA; Jaeger H; Nagel AM; Ziegler AE; Simons D; Schlemmer HP; Lehmann-Horn F; Jurkat-Rott K; Weber MA
    Acta Myol; 2017 Mar; 36(1):2-13. PubMed ID: 28690388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prednisone therapy in Becker's muscular dystrophy.
    Johnsen SD
    J Child Neurol; 2001 Nov; 16(11):870-1. PubMed ID: 11732779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Treatment for Duchenne Muscular Dystrophy.
    Aschenbrenner DS
    Am J Nurs; 2017 Jun; 117(6):22-23. PubMed ID: 28541984
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy.
    Parreira SL; Resende MB; Zanoteli E; Carvalho MS; Marie SK; Reed UC
    Arq Neuropsiquiatr; 2010 Oct; 68(5):683-8. PubMed ID: 21049175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steroid therapy and cardiac function in Duchenne muscular dystrophy.
    Markham LW; Spicer RL; Khoury PR; Wong BL; Mathews KD; Cripe LH
    Pediatr Cardiol; 2005; 26(6):768-71. PubMed ID: 15990951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.